Association of SLC polymorphism with histology and overall
survival
We further assessed the role of SLC variants in predicting median
survival of lung carcinoma patients based on histological subtypes. On
analysis, we noted that ADCC patients harboring mutant genotype
(AA ) showed better survival outcomes compared to the ADCC
subjects with wild-type genotype (GG ) for SLC19A1
G80A (MST=9.4 versus 8.8,Log-rank p=0.2) as shown inTable 4 . After applying the cox regression model, there was a
decreased hazard ratio for lung cancer patients
(HR1=0.60, 95%CI=0.36-1.00, p=0.04 ).
For SLCO1B1 A388G , patients diagnosed with SQCC
and harboring the mutant genotype (GG ) showed poor survival
outcomes when compared to combined wild type and heterozygous genotype
(AA+AG ) (MST=6.8 months versus 7.5 months; log-rank p=0.42).
After multivariate analysis, the overall death risk of patients carryingGG genotype at A388G was 1.54 times
higher than individuals with AA+AG genotype (HR=1.54, 95%
CI=0.99-2.39; p=0.05) . However, on analyzing the association ofSLC19A1 G80A polymorphism with SCLC histology,
our results depicted increased survival in the patients harboring mutant
genotype (AA ) as compared to the SCLC subjects having wild type
genotype (GG ) (MST=9.6 months versus 7.6 months, p=0.34). After
multivariate analysis, such patients had a low death ratio than SCLC
subjects carrying the wild genotype (GG ) (HR=0.22,
95%CI=0.05-0.93, p=0.04, Table 4, Figure 4 ). Similar results
were also obtained when the recessive model was applied (HR=0.30,
95%CI=0.11-0.84, p=0.02) .None of the other SCLC patients
showed prognostic significance for the SLCO1B1
A388G, T521C, and SLCO1B3
A1683-5676G polymorphism (Supplementary Table
1).